Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 187.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,464 shares of the life sciences company’s stock after purchasing an additional 22,455 shares during the quarter. Wealthfront Advisers LLC’s holdings in Illumina were worth $4,605,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. WCM Investment Management LLC lifted its stake in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after buying an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock valued at $454,617,000 after purchasing an additional 27,618 shares during the last quarter. Geode Capital Management LLC boosted its stake in Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after purchasing an additional 48,018 shares during the period. Primecap Management Co. CA grew its position in Illumina by 3.6% in the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after purchasing an additional 87,599 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $84.05 on Friday. Illumina, Inc. has a 52-week low of $80.18 and a 52-week high of $156.66. The stock has a market capitalization of $13.31 billion, a price-to-earnings ratio of -10.94, a PEG ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock’s fifty day simple moving average is $114.52 and its 200 day simple moving average is $130.20.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ILMN shares. Stephens reaffirmed an “overweight” rating and set a $156.00 price target on shares of Illumina in a report on Tuesday. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and cut their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a research note on Friday, February 28th. Royal Bank of Canada cut their price objective on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.